Los Angeles-based Keck Medicine of USC will assess the feasibility of providing home-based immunotherapy to patients with non-small cell lung cancer via a new clinical trial.
Currently, immunotherapies are only administered intravenously in healthcare settings. The study will assess whether a new formulation of atezolizumab can be safely and effectively administered subcutaneously by nurses at patients' homes.
The clinical trial is the first to assess whether a subcutaneous immunotherapy can be administered at home.
"Many types of drugs are now being delivered subcutaneously at home for several conditions, and we hypothesize that this method of drug delivery can also be successful for cancer patients," lead investigator Jorge Nieva, MD, a medical oncologist and lung cancer specialist with Keck Medicine, said in a March 28 news release.
Learn more here.